Skip to Content

Cetirizine (Systemic)

Medically reviewed by Drugs.com. Last updated on Jul 30, 2020.

Pronunciation

(se TI ra zeen)

Index Terms

  • Cetirizine Hydrochloride
  • P-071
  • Quzyttir
  • UCB-P071

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as hydrochloride:

Allergy Relief: 10 mg

ZyrTEC Allergy: 10 mg

Solution, Intravenous, as hydrochloride [preservative free]:

Quzyttir: 10 mg/mL (1 mL)

Solution, Oral, as hydrochloride:

All Day Allergy Childrens: 5 mg/5 mL (118 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben]

All Day Allergy Childrens: 5 mg/5 mL (118 mL [DSC]) [dye free, gluten free; contains methylparaben, propylene glycol, propylparaben; grape flavor]

Allergy Relief Childrens: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, dye free, gluten free, sugar free; contains methylparaben, propylene glycol, propylparaben; grape flavor]

Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, sugar free; contains methylparaben, propylene glycol, propylparaben]

Cetirizine HCl Allergy Child: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Cetirizine HCl Childrens: 5 mg/5 mL (118 mL) [contains methylparaben, propylene glycol, propylparaben]

Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (118 mL, 120 mL) [contains methylparaben, propylene glycol, propylparaben; grape flavor]

Cetirizine HCl Hives Relief: 5 mg/5 mL (120 mL) [alcohol free, sugar free; contains methylparaben, propylene glycol, propylparaben; grape flavor]

GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate, sorbitol]

ZyrTEC Childrens Allergy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate]

ZyrTEC Childrens Allergy: 5 mg/5 mL (118 mL, 236 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Generic: 5 mg/5 mL (120 mL, 473 mL, 480 mL)

Tablet, Oral, as hydrochloride:

All Day Allergy: 10 mg [contains corn starch]

Allergy Relief Cetirizine: 10 mg

Allergy Relief/Indoor/Outdoor: 10 mg [scored]

GoodSense All Day Allergy: 10 mg [contains corn starch, fd&c blue #1 aluminum lake]

ZyrTEC Allergy: 10 mg

Generic: 5 mg, 10 mg

Tablet Chewable, Oral, as hydrochloride:

All Day Allergy Childrens: 10 mg [DSC]

Cetirizine HCl Childrens: 5 mg, 10 mg [contains aspartame, fd&c yellow #6 aluminum lake]

Generic: 5 mg, 10 mg

Tablet Disintegrating, Oral, as hydrochloride:

ZyrTEC Allergy: 10 mg

ZyrTEC Allergy Childrens: 10 mg

ZyrTEC Allergy Childrens: 10 mg [citrus flavor]

Brand Names: U.S.

  • All Day Allergy Childrens [OTC] [DSC]
  • All Day Allergy [OTC]
  • Allergy Relief Cetirizine [OTC]
  • Allergy Relief Childrens [OTC]
  • Allergy Relief [OTC]
  • Allergy Relief/Indoor/Outdoor [OTC]
  • Cetirizine HCl Allergy Child [OTC]
  • Cetirizine HCl Childrens Alrgy [OTC]
  • Cetirizine HCl Childrens [OTC]
  • Cetirizine HCl Hives Relief [OTC]
  • GoodSense All Day Allergy [OTC]
  • Quzyttir
  • ZyrTEC Allergy Childrens [OTC]
  • ZyrTEC Allergy [OTC]
  • ZyrTEC Childrens Allergy [OTC]

Pharmacologic Category

  • Histamine H1 Antagonist
  • Histamine H1 Antagonist, Second Generation
  • Piperazine Derivative

Pharmacology

Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract

Absorption

Rapid

Distribution

Children: 0.7 L/kg ; Adults: 0.56 L/kg (Simons 1999)

Metabolism

Limited hepatic

Excretion

Urine (70%; 50% as unchanged drug); feces (10%)

Onset of Action

Suppression of skin wheal and flare: Oral: 20 to 60 minutes.

Time to Peak

Serum: Oral: 1 hour; IV: 108 seconds.

Duration of Action

Suppression of skin wheal and flare: Oral: ≥24 hours.

Half-Life Elimination

Children: 6.2 hours; Adults: 8 hours

Protein Binding

Plasma: Mean: 93%

Use: Labeled Indications

Oral:

Allergic rhinitis: Relief of symptoms associated with allergic rhinitis.

Urticaria, chronic spontaneous: Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria.

Injection:

Urticaria, acute: Treatment of acute urticaria.

Off Label Uses

Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms)

Based on joint guidelines from the American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma & Immunology, and Joint Council of Allergy, Asthma and Immunology on the diagnosis and management of anaphylaxis and guidelines from the World Allergy Organization on anaphylaxis, cetirizine may be used as adjunctive treatment, although should not be used as monotherapy or as first-line therapy of anaphylaxis.

Angioedema, acute allergic or recurrent idiopathic

Clinical experience suggests the utility of second-generation H1 receptor antagonists (eg, cetirizine) for the treatment of acute allergic or recurrent idiopathic angioedema [Cicardi 2014], [James 2017].

Infusion reaction, premedication

Clinical experience suggests the utility of second-generation H1 receptor antagonists (eg, cetirizine) as an adjunct to premedication prior to the infusion of certain chemotherapy agents (eg, certain taxanes) or biologics to prevent infusion reactions [Castells 2019], [Durham 2018], [Kirkham 2019].

Contraindications

Hypersensitivity to cetirizine, hydroxyzine, levocetirizine, or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to piperazine derivatives; severe renal impairment (CrCl <10 mL/minute).

Dosing: Adult

Allergic rhinitis or conjunctivitis: Oral: 10 mg once daily; alternatively, may be given as needed 2 to 5 hours before exposure to allergen, although this may be less effective than daily administration (deShazo 2020).

OTC labeling (patient-guided therapy for symptoms of hay fever or other upper respiratory allergies): 5 to 10 mg once daily (maximum: 10 mg/day).

Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms) (off-label use): Note: Do not use for initial or sole treatment of anaphylaxis because H1 antihistamines do not relieve upper or lower airway obstruction or shock (AAAAI/ACAAI/JCAAI [Lieberman 2015]; Sheikh 2007; WAO [Simons 2011]; WAO [Simons 2015]).

Oral: 10 mg as a single dose (AAAAI/ACAAI/JCAAI [Lieberman 2015]; WAO [Simons 2011]).

Angioedema, acute allergic or recurrent idiopathic (off-label use): Note: Not indicated for angioedema with anaphylaxis; use epinephrine if anaphylaxis symptoms are present (ie, risk of airway or cardiovascular compromise is present) (James 2017; Zuraw 2019).

Oral: 10 mg once or twice daily; may increase up to 20 mg twice daily (Cicardi 2014; James 2017; Zuraw 2019).

Infusion reaction, premedication (adjunct) (alternative agent) (off-label use): Note: Used in some protocols as an alternative to a sedating antihistamine (eg, diphenhydramine). An optimal premedication regimen has not been identified; refer to institutional protocols as variations exist (Castells 2019; Durham 2018; Kirkham 2019).

Oral: 10 mg typically administered 30 to 60 minutes prior to infusion of certain chemotherapy agents or biologics; may be given with an H2 antihistamine (eg, ranitidine) and/or a glucocorticoid (Castells 2019; Durham 2018).

Urticaria (acute and chronic spontaneous):

Acute:

Oral (off label): Initial: 10 mg once daily. If symptom control is inadequate, may increase to 10 mg twice daily (Asero 2020; Zuberbier 2018).

IV: 10 mg once daily as needed. If symptom control is inadequate, may increase to 10 mg twice daily (Asero 2020; Zuberbier 2018). Switch to scheduled oral dosing when feasible.

Chronic spontaneous:

Oral: Initial: 10 mg once daily. If symptom control is inadequate, may increase in increments of 10 mg/day every 1 to 4 weeks up to 20 mg twice daily. Reevaluate necessity for continued treatment periodically (Khan 2020; Zuberbier 2018).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Upper respiratory allergies, urticaria: Oral: 5 mg once daily (maximum dose: 5 mg daily). The previously available prescription product recommended a maximum dose of 10 mg once daily in patients <77 years of age or 5 mg once daily in patients ≥77 years of age (Zyrtec Prescribing Information, 2006).

Dosing: Pediatric

Allergic symptoms, hay fever:

Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily; maximum daily dose: 5 mg/day.

Children ≥6 years and Adolescents: Oral: 5 to 10 mg once daily.

Anaphylaxis; adjunctive for cutaneous symptoms: Limited data available (Canadian Paediatric Society [Cheng 2011]): Note: Do not use for initial or sole treatment of anaphylaxis; H1 antihistamines are not effective for upper or lower airway obstruction or shock (AAAAI/ACAAI/JCAAI [Lieberman 2015]; WAO [Simons 2011]; WAO [Simons 2015]). If cutaneous symptoms persist, dose may be repeated in 24 hours (see Urticaria, acute dosing).

Infants ≥6 months and Children <2 years: Oral: 2.5 mg once.

Children 2 to 5 years: Oral 2.5 to 5 mg once.

Children >5 years and Adolescents: Oral: 5 to 10 mg once.

Rhinitis, allergic(perennial):

Infants 6 to <12 months: Oral: 2.5 mg once daily.

Children 12 to 23 months: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.

Urticaria, acute:

IV:

Infants ≥6 months to Children ≤5 years: 2.5 mg every 24 hours.

Children 6 to 11 years: 5 mg or 10 mg every 24 hours; reserve higher dose for more severe symptoms.

Children ≥12 years and Adolescents: 10 mg every 24 hours.

Oral: Limited data available (Canadian Paediatric Society [Cheng 2011]):

Infants ≥6 months and Children <2 years: Oral: 2.5 mg once daily.

Children 2 to 5 years: Oral: 2.5 to 5 mg once daily.

Children >5 years and Adolescents: Oral: 5 to 10 mg once daily.

Urticaria, chronic spontaneous: Limited data available in Children >5 years and Adolescents. Note: Considered first-line therapy for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider increasing the dose of cetirizine (as age and weight permits) as second-line treatment rather than changing therapy (Zuberbier 2018).

Infants 6 to <12 months: Oral: 2.5 mg once daily.

Infants ≥12 months and Children <2 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.

Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily; maximum daily dose: 5 mg/day.

Children 6 to 11 years: Oral: 5 mg once daily or twice daily (Caffarelli 2019; Del Pozzo-Magaña 2017)

Children ≥12 years and Adolescents: Oral: 10 mg once daily (Caffarelli 2019; Del Pozzo-Magaña 2017)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Administration

Oral: May be administered with or without food.

Chewable tablet: Chew tablet before swallowing; may be taken with or without water.

IV: Injection: For IV use only; do not administer IM or SubQ; administer as an IV push over 1 to 2 minutes.

Storage

Capsule, tablet, oral solution, injection: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Injection: Discard unused portion.

Drug Interactions

Acetylcholinesterase Inhibitors: Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Monitor therapy

Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Monitor therapy

Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Monitor therapy

Amphetamines: May diminish the sedative effect of Antihistamines. Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Monitor therapy

Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combination

Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Consider therapy modification

Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Monitor therapy

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Consider therapy modification

Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Monitor therapy

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Consider therapy modification

Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Cannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy

Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Avoid combination

CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Monitor therapy

Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Consider therapy modification

Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Avoid combination

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Consider therapy modification

Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Monitor therapy

Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Monitor therapy

Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Avoid combination

Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination

Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination

Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Monitor therapy

Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Consider therapy modification

Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Avoid combination

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Methotrimeprazine: May enhance the CNS depressant effect of CNS Depressants. CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Monitor therapy

Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Monitor therapy

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Avoid combination

Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interupt oxybate salt treatment during short-term opioid use. Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Consider therapy modification

Pilsicainide: May increase the serum concentration of Cetirizine (Systemic). Cetirizine (Systemic) may increase the serum concentration of Pilsicainide. Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Monitor therapy

Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Avoid combination

Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Avoid combination

Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Avoid combination

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Monitor therapy

Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Avoid combination

Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Monitor therapy

Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Avoid combination

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Monitor therapy

Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Consider therapy modification

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Consider therapy modification

Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Avoid combination

Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Monitor therapy

Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Avoid combination

Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Consider therapy modification

Test Interactions

May cause false-positive serum TCA screen. May suppress the wheal and flare reactions to skin test antigens.

Adverse Reactions

>10%: Nervous system: Drowsiness (adolescents and adults: 11% to 14%; children: 2% to 4%), headache (children: 14%; adults: <1%)

1% to 10%:

Cardiovascular: Cardiac failure (<2%), chest pain (<2%), edema (<2%), facial edema (<2%), flushing (<2%), hypertension (<2%), lower extremity edema (<2%), palpitations (<2%), peripheral edema (<2%), syncope (<2%), tachycardia (<2%)

Dermatologic: Acne vulgaris (<2%), alopecia (<2%), bullous rash (<2%), cutaneous nodule (<2%), dermatitis (<2%), diaphoresis (<2%), eczema (<2%), erythematous rash (<2%), furunculosis (<2%), hyperkeratosis (<2%), hypertrichosis (<2%), maculopapular rash (<2%), pallor (<2%), pruritus (<2%), seborrhea (<2%), skin photosensitivity (<2%), skin rash (<2%), urticaria (<2%), xeroderma (<2%)

Endocrine & metabolic: Decreased libido (<2%), dehydration (<2%), diabetes mellitus (<2%), heavy menstrual bleeding (<2%), hot flash (<2%), increased thirst (<2%), intermenstrual bleeding (<2%), weight gain (<2%)

Gastrointestinal: Abdominal pain (children: 4% to 6%), xerostomia (adolescents and adults: 5%), nausea (children: 3%), diarrhea (children: 2% to 3%), vomiting (children: 2% to 3%), ageusia (<2%), anorexia (<2%), aphthous stomatitis (<2%), constipation (<2%), dental caries (<2%), dysgeusia (<2%), dyspepsia (<2%), enlargement of abdomen (<2%), eructation (<2%), flatulence (<2%), gastritis (<2%), hemorrhoids (<2%), increased appetite (<2%), melena (<2%), sialorrhea (<2%), stomatitis (<2%), tongue discoloration (<2%)

Genitourinary: Cystitis (<2%), dysmenorrhea (<2%), dysuria (<2%), hematuria (<2%), leukorrhea (<2%), mastalgia (<2%), urinary frequency (<2%), urinary incontinence (<2%), urinary retention (<2%), urinary tract infection (<2%), vaginitis (<2%)

Hematologic & oncologic: Hemophthalmos (<2%), lymphadenopathy (<2%), purpuric disease (<2%), rectal hemorrhage (<2%)

Hepatic: Hepatic insufficiency (<2%)

Hypersensitivity: Angioedema (<2%), tongue edema (<2%)

Nervous system: Insomnia (≤9%), fatigue (4% to 6%), malaise (≤4%), dizziness (adolescents and adults: 2%), abnormality in thinking (<2%), agitation (<2%), altered sense of smell (<2%), amnesia (<2%), anxiety (<2%), ataxia (<2%), confusion (<2%), depersonalization (<2%), depression (<2%), emotional lability (<2%), euphoria (<2%), hyperesthesia (<2%), hypertonia (<2%), hypoesthesia (<2%), impaired concentration (<2%), migraine (<2%), myasthenia (<2%), nervousness (<2%), nightmares (<2%), pain (<2%), paralysis (<2%), paresthesia (<2%), rigors (<2%), sleep disorder (<2%), twitching (<2%), vertigo (<2%), voice disorder (<2%)

Neuromuscular & skeletal: Arthralgia (<2%), arthritis (<2%), asthenia (<2%), back pain (<2%), hyperkinetic muscle activity (<2%), lower limb cramp (<2%), myalgia (<2%), myelitis (<2%), osteoarthrosis (<2%), tremor (<2%)

Ophthalmic: Accommodation disturbance (<2%), blepharoptosis (<2%), blindness (<2%), conjunctivitis (<2%), eye pain (<2%), glaucoma (<2%), periorbital edema (<2%), visual field defect (<2%), xerophthalmia (<2%)

Otic: Deafness (<2%), otalgia (<2%), ototoxicity (<2%), tinnitus (<2%)

Renal: Polyuria (<2%)

Respiratory: Pharyngitis (children: 6%), epistaxis (children: 4%), bronchospasm (children: 3%), bronchitis (<2%), dyspnea (<2%), hyperventilation (<2%), increased bronchial secretions (<2%), nasal polyposis (<2%), pneumonia (<2%), respiratory system disorder (<2%), rhinitis (<2%), sinusitis (<2%), upper respiratory tract infection (<2%)

Miscellaneous: Fever (<2%)

<1%: Feeling hot, hyperhidrosis, presyncope

Frequency not defined:

Hepatic: Increased serum transaminases

Nervous system: Irritability

Miscellaneous: Fussiness in an infant or toddler

Postmarketing: Aggressive behavior, anaphylaxis, cholestasis, glomerulonephritis, hallucination, hemolytic anemia, hepatitis, increased serum bilirubin, orofacial dyskinesia, sedated state, seizure, severe hypotension, suicidal ideation, suicidal tendencies, thrombocytopenia

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).

Disease-related concerns:

• Hepatic impairment: Use with caution.

• Renal impairment: Use with caution; consider dosage adjustment.

Concurrent drug therapy issues:

• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.

Special populations:

• Elderly: Use with caution in elderly patients; may be more sensitive to adverse effects.

Monitoring Parameters

Relief of symptoms, sedation and anticholinergic effects

Pregnancy Considerations

Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Cetirizine may be used when a second generation antihistamine is needed. The lowest effective dose should be used (Powell 2015; Scadding 2017; Wallace 2008; Zuberbier 2018).

Patient Education

What is this drug used for?

• It is used to ease allergy signs.

• It is used to treat hives.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Fatigue

• Dry mouth

• Loss of strength and energy

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions